13 pending office actions • 4 clients
| Client (Assignee) | Pending OAs |
|---|---|
| AstraZeneca AB | 8 |
| AstraZeneca AB | 3 |
| Keymed Biosciences Co., Ltd. | 1 |
| MedImmune, LLC | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18855182 | PREDICTING ALBUMINURIA USING MACHINE LEARNING | AstraZeneca AB | HEIN, DEVIN C | 3686 | Non-Final OA | Oct 08, 2024 |
| 18253280 | STEROID SPARING | AstraZeneca AB | HADDAD, MAHER M | 1641 | Non-Final OA | May 17, 2023 |
| 18031731 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | Keymed Biosciences Co., Ltd. | HADDAD, MAHER M | 1641 | Non-Final OA | Apr 13, 2023 |
| 18248486 | Adjuvant Durvalumab in Combination with Chemotherapy for Treatment of Cancer | AstraZeneca AB | CHHAY, BONIRATH | 1645 | Non-Final OA | Apr 10, 2023 |
| 18248280 | TREATMENT OF FLARES IN LUPUS | AstraZeneca AB | XIE, XIAOZHEN | 1674 | Non-Final OA | Apr 07, 2023 |
| 17926235 | TUMOR MUTATIONAL BURDEN ASSOCIATED WITH SENSITIVITY TO IMMUNOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA | AstraZeneca AB | AEDER, SEAN E | 1642 | Non-Final OA | Nov 18, 2022 |
| 18046173 | COMBINATION | AstraZeneca AB | REDDIG, PETER J | 1646 | Final Rejection | Oct 13, 2022 |
| 17783463 | Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 | MedImmune, LLC | HILL, KEVIN KAI | 1638 | Non-Final OA | Jun 08, 2022 |
| 17755801 | TYPE I INTERFERON INHIBITION IN SYSTEMIC LUPUS ERYTHEMATOSUS | AstraZeneca AB | KIM, YUNSOO | 1641 | Final Rejection | May 09, 2022 |
| 17765585 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES | AstraZeneca AB | CHATTIN, AMY MARIE | 1643 | Non-Final OA | Mar 31, 2022 |
| 17754258 | COMBINATION TREATMENT FOR CANCER | AstraZeneca AB | DARPOLOR, JOSEPHINE KEBBEH | 1642 | Non-Final OA | Mar 29, 2022 |
| 17529574 | Compositions and Methods for Treating Late Stage Lung Cancer | AstraZeneca AB | HECK, BRYAN WILLIAM | 1643 | Non-Final OA | Nov 18, 2021 |
| 17318017 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES | AstraZeneca AB | BUTTICE, AUDREY L | 1647 | Final Rejection | May 12, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial